Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case
We all have bad days. Immunovant, Inc. (NASDAQ:IMVT) had its latest bad day on September 23 after a clinical-trial setback, sending the shares lower.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 9,160,801 | $309,451,858 | -2% | 5.04% |
| 2. | Farallon Capital Thomas Steyer | 6,471,000 | $218,590,380 | +12% | 0.94% |
| 3. | Two Seas Capital Sina Toussi | 4,612,692 | $155,816,736 | +47% | 1.8% |
| 4. | Baker Bros. Advisors Julian Baker And Felix Baker | 2,770,377 | $93,583,335 | -50% | 0.44% |
| 5. | ADAR1 Capital Management Daniel Schneeberger | 2,115,502 | $71,461,658 | -10% | 3.04% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.00 | 16,666,666 | $349,999,986.00 | 113,317,007 | 2025-12-12 | Filing | |
| $20.00 | 16,845,010 | $336,900,200.00 | 96,650,341 | 2025-01-13 | Filing | |
| $38.00 | 1,526,316 | $58,000,008.00 | 79,805,331 | 2023-10-02 | Filing | |
| $6.00 | 416,667 | $2,500,002.00 | 73,805,331 | 2022-10-06 | Filing | |
| $5.60 | 15,000 | $84,000.00 | 20,000 | 2022-09-30 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.00 | 3,000 | $108,000.00 | 116,731 | 2026-11-11 | Filing | |
| $28.50 | 6,606 | $188,271.00 | 234,192 | 2026-10-28 | Filing | |
| $28.94 | 2,595 | $75,099.30 | 198,937 | 2026-10-21 | Filing | |
| $32.06 | 1,596 | $51,167.76 | 201,532 | 2026-10-07 | Filing | |
| $32.06 | 2,213 | $70,948.78 | 203,128 | 2026-10-07 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,704,154 | $530,486,333 | 0.02% | |
| 2. | 7,425,771 | $250,842,555 | 0% | |
| 3. | 5,684,840 | $192,033,921 | 0.01% | |
| 4. | 4,457,988 | $150,590,835 | 4.25% | |
| 5. | 4,264,743 | $144,063,019 | 0.01% |